News

Imbruvica is approved for use in four indications to treat three different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom’s macroglobulinemia. AbbVie chairman

The BLA is based on results from the LEOPOLD clinical trials, which evaluated BAY 81-8973 in adults and children using two- and three-times-per-week prophylaxis dosing regimens. The trials,

The company said that the label has also been updated to include efficacy data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). The CAPiTA trial showed statistically

The deal will see evaluation of the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA in US), in combination with Eisai oncology compounds lenvatinib mesylate (Lenvima)

The company said that Opdivo is the first and only programed death receptor-1 (PD-1) therapy to show overall survival in previously treated metastatic squamous NSCLC. The approval is

The deal strengthens AstraZeneca’s aclidinium respiratory franchise and builds on the acquisition of Almirall’s respiratory portfolio in 2014 by extending the company’s development and commercialization rights into the

Upon effectiveness of the deal, Islet will be granted exclusive rights to remogliflozin in the global territory outside of Japan, Korea, Taiwan, China, and Latin America. As part

Xydalba is approved to treat ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes. Actavis executive vice

Start-up procedures have already been started and patient enrolment is expected to be initiated in the second quarter of 2015. Both the parties will jointly conduct the trial